APOC3, apolipoprotein C3, 345

N. diseases: 153; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0202236
Disease: Triglycerides measurement
Triglycerides measurement 		0.100 GeneticVariation phenotype GWASDB Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. 23063622 2012
CUI: C0523465
Disease: Serum albumin measurement
Serum albumin measurement 		0.100 GeneticVariation phenotype GWASDB Genome-wide association study identifies multiple loci influencing human serum metabolite levels. 22286219 2012
CUI: C1445957
Disease: Serum total cholesterol measurement
Serum total cholesterol measurement 		0.100 GeneticVariation phenotype GWASDB Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. 23063622 2012
CUI: C0020443
Disease: Hypercholesterolemia
Hypercholesterolemia 		0.460 Biomarker disease GENOMICS_ENGLAND
CUI: C0002726
Disease: Amyloidosis
Amyloidosis 		0.310 Biomarker disease GENOMICS_ENGLAND Thus, fibrate therapy, which reduces hepatic APOC3 transcription, may delay amyloid deposition in affected patients. 26790392 2016
CUI: C3151467
Disease: Apolipoprotein C-III Deficiency
Apolipoprotein C-III Deficiency 		0.610 GeneticVariation disease UNIPROT Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. 2022742 1991
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X 		0.300 Biomarker disease RGD Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. 16298371 2006
CUI: C0011854
Disease: Diabetes Mellitus, Insulin-Dependent
Diabetes Mellitus, Insulin-Dependent 		0.270 Biomarker disease RGD Lowering apolipoprotein CIII delays onset of type 1 diabetes. 21670290 2011
CUI: C0008370
Disease: Cholestasis
Cholestasis 		0.200 Biomarker disease RGD Effect of bile duct obstruction on the expression of intestinal mRNA related to cholesterol and bile acid metabolism in the rat. 17201892 2007
CUI: C0020550
Disease: Hyperthyroidism
Hyperthyroidism 		0.200 Biomarker disease RGD Role of thyroid hormone in the expression of apolipoprotein A-IV and C-III genes in rat liver. 8429259 1993
CUI: C0020676
Disease: Hypothyroidism
Hypothyroidism 		0.200 Biomarker disease RGD We therefore measured the transcriptional activity of the apoA-IV and apoC-III genes and the abundance of their nuclear RNA and total cellular mRNA in livers of control rats and rats made hyper- and hypothyroid. 8429259 1993
CUI: C0021655
Disease: Insulin Resistance
Insulin Resistance 		0.200 Therapeutic phenotype RGD Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. 15007394 2004
CUI: C0342883
Disease: Cholesteryl Ester Transfer Protein Deficiency
Cholesteryl Ester Transfer Protein Deficiency 		0.320 GermlineCausalMutation disease ORPHANET Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. 2022742 1991
CUI: C0020443
Disease: Hypercholesterolemia
Hypercholesterolemia 		0.460 Biomarker disease HPO
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia 		0.200 Biomarker disease HPO
CUI: C0542037
Disease: Hypotriglyceridemia
Hypotriglyceridemia 		0.110 Biomarker disease HPO
CUI: C0853085
Disease: Decreased LDL cholesterol concentration
Decreased LDL cholesterol concentration 		0.100 Biomarker phenotype HPO
CUI: C4551591
Disease: Increased HDL cholesterol concentration
Increased HDL cholesterol concentration 		0.100 Biomarker phenotype HPO
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases 		0.400 GeneticVariation group LHGDN Serum apoCIII concentration was highly correlated with multiple changes in lipids and lipoproteins that resulted in an adverse cardiovascular disease risk profile. 15375785 2004
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.400 GeneticVariation disease LHGDN ApoC-III gene polymorphisms and risk of coronary artery disease. 12235176 2002
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.400 GeneticVariation disease LHGDN Therefore, the present study aimed to elucidate the relationship of four single nucleotide polymorphisms (SNPs) in the Apo11q cluster, namely the -75G>A, +83C>T SNPs in the APOA1 gene, the Sac1 SNP in the APOC3 gene and the S19W variant in the APOA5 gene to plasma lipids and CAD in 190 affected sibling pairs (ASPs) belonging to Asian Indian families with a strong CAD history. 18801202 2008
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.400 Biomarker disease LHGDN Genetic epistasis in the VLDL catabolic pathway is associated with deleterious variations on triglyceridemia in obese subjects. 17342071 2007
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.400 GeneticVariation disease LHGDN The carriership for the -455C variant multiplied the probability of CAD in MS in an allele-specific way and was associated with increased apoC-III and TG levels. 14563827 2003
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X 		0.300 Biomarker disease LHGDN This study investigated the dose-dependent effect of rosuvastatin on VLDL apoC-III transport in men with the metabolic syndrome. 18509206 2008
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia 		0.200 GeneticVariation disease LHGDN Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation. 12118856 2002